GIRI GI Research Institute

Vancouver, British Columbia V6Z 2K5

0 studies enrolling now · 22 studies all time

What they study most

Cancer, Chronic Genotype 1a or 1b HCV Infection, Chronic Hepatitis B, Chronic Hepatitis C, Colitis, Ulcerative, Colonic Diseases, Compensated Cirrhosis, Crohn Disease, Crohn's Disease, Eosinophilic Esophagitis, Hepatitis C, Chronic, Nonalcoholic Fatty Liver Disease

Studies at this site

• ABTECT - Maintenance — Running, not enrolling
• Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment. — Running, not enrolling
• Determination of the Optimal Treatment Target in Ulcerative Colitis — Running, not enrolling
• Phase 2a Evaluation of Safety, Tolerability, and Pharmacokinetics of PLN-74809 in Patients With Primary Sclerosing Cholangitis (PSC) — Completed
• ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 — Completed
• Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis — Completed
• Metabolic Interventions to Resolve Non-alcoholic Steatohepatitis (NASH) With Fibrosis (MIRNA) — Completed
• Open-Label Extension and Safety Study for Participants With Crohn's Disease Previously Enrolled in the Etrolizumab Phase III Study GA29144 — Stopped early
• Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Participants With Crohn's Disease (CD) — Completed
• Study Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis — Completed
• Efficacy, Safety, and Pharmacokinetics of APT-1011 in Subjects With Eosinophilic Esophagitis (EoE) — Completed
• A Study to Assess Whether Etrolizumab is a Safe and Efficacious Treatment for Participants With Moderately to Severely Active Crohn's Disease — Completed
• A Study of ABI-H2158-containing Regimens in Participants With Chronic Hepatitis B Virus Infection — Stopped early
• A Study to Evaluate the Efficacy and Safety of Vedolizumab in the Treatment of Chronic Pouchitis — Completed
• Long-Term Safety Of PF-00547659 In Ulcerative Colitis — Completed
• Safety and Efficacy of Selonsertib in Adults With Nonalcoholic Steatohepatitis (NASH) and Bridging (F3) Fibrosis — Stopped early
• Trial of Simplified Treatment Monitoring for 8 Weeks Glecaprevir/Pibrentasvir in Chronic Hepatitis C Patients — Completed
• Vedolizumab IV 300 mg in the Treatment of Fistulizing Crohn's Disease — Completed
• A Phase 2a, Proof-of-Concept Study of GIC-1001 in the Management of Visceral Pain During Sedation-Free, Full Colonoscopy — Completed
• Gilead Sustained Virologic Response (SVR) Registry — Completed
• GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype — Stopped early
• GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection — Completed